Akebia Therapeutics, Inc. (AKBA) vs BioAge Labs, Inc. (BIOA)
Akebia Therapeutics, Inc. and BioAge Labs, Inc. are both Drug Manufacturers Specialty & Generic companies. BioAge Labs, Inc. is the larger, with a market value of $337.4M against $254.7M — 1.3× the size. Akebia Therapeutics, Inc. has the higher net margin (−13.5% vs −912.3%) and the higher return on invested capital (0.00% vs −118.3%). Across the 16 metrics below, Akebia Therapeutics, Inc. leads on 10 and BioAge Labs, Inc. on 6.
Valuation
Profitability
| Metric | AKBA | BIOA | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| Gross margin | 79.63% | 100.00% | 53.94% |
| Operating margin | (6.90%) | (1,026.28%) | 0.00% |
| Net margin | (13.54%) | (912.25%) | 0.00% |
| Free cash flow margin | 18.38% | (2,345.11%) | 0.00% |
| Return on equity | (109.38%) | (28.21%) | (0.40%) |
| Return on assets | (8.53%) | (26.27%) | (3.32%) |
| Return on invested capital | 0.00% | (118.25%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack